Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Objectives To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response and efficacy of E6742 in a phase I/II study in patients with systemic lupus erythematosus (SLE).Methods Two sequential cohorts of patients with SLE were enrolled and randomised to 12 weeks of two times per day...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomonori Ishii, Yoshiya Tanaka, Atsushi Kumanogoh, Tatsuya Atsumi, Shizuo Akira, Fumitoshi Tago, Mari Aoki, Shintaro Yamamuro
Format: Article
Language:English
Published: BMJ Publishing Group 2024-09-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/3/e004701.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items